Lv5
1080 积分 2022-07-16 加入
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial
19小时前
已完结
Post-resection recurrence of hepatocellular carcinoma in cirrhotic patients: Is thrombocytopenia a risk factor for recurrence?
1个月前
已完结
Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization
1个月前
已完结
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial
2个月前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2个月前
已完结
Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival
2个月前
已完结
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
2个月前
已完结
Establishing hepatic decompensation as a meaningful clinicaloutcome during systemic therapy for hepatocellular carcinoma
3个月前
已完结
Establishing hepatic decompensation as a meaningful clinicaloutcome during systemic therapy for hepatocellular carcinoma
3个月前
已完结
Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study
3个月前
已完结
皖公网安备34019202002308
